You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 276 No. 6, August 14, 1996 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Clinical Cardiology
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Should Survivors of Myocardial Infarction With Low Ejection Fraction Be Routinely Referred to Arrhythmia Specialists?

William G. Stevenson, MD; Paul M. Ridker, MD

JAMA. 1996;276(6):481-485.


Abstract

Because survivors of myocardial infarction are at risk for ventricular arrhythmias and sudden death, physicians must decide whether to refer these patients to specialists for arrhythmia assessment and therapy. However, this decision is complex as few randomized data are available concerning either diagnostic or therapeutic options. Therefore, we modeled the potential impact of current arrhythmia detection and management strategies on mortality in survivors of myocardial infarction with reduced left ventricular function who are managed in a contemporary manner. Based on recent data we estimated that the mortality for myocardial infarction survivors with left ventricular ejection fraction less than 0.40 is 20% over 3.5 years and that half of the deaths are sudden. The sensitivity and specificity of a Holter electrocardiogram (ECG), a signal-averaged ECG, and an invasive electrophysiology study for predicting sudden death were obtained from a literature review of trials published after 1990 that included more than 300 patients. A series of models were constructed to predict mortality achieved by different arrhythmia management strategies that reduced sudden death by 50% and 75%—reductions estimated to be within the range for amiodarone and implantable defibrillators. We found that, when routinely applied to all infarct survivors with depressed ventricular function, a therapy that reduces sudden death by 50% with 1% fatal adverse effects (potentially amiodarone) saves approximately 1 life for every 25 patients treated. Therapy that reduces sudden death by 75% with 2% fatal adverse effects (potentially implantable defibrillators) saves 1 life for every 14 patients treated. Using Holter ECG recordings, a signal-averaged ECG, or an invasive electrophysiology study to select higher-risk groups, 1 life can be saved for every 4 to 11 patients treated, and the negative impact of adverse effects can be reduced. However, to achieve this benefit, additional and potentially invasive arrhythmia testing must be applied to 28 to 47 patients for each life saved. Thus, with contemporary management of acute myocardial infarction, the risk of sudden death for survivors is sufficiently low that broad application of available antiarrhythmic therapies has limited potential for further improving survival, particularly if therapy also has significant adverse effects. Thus, routine referral to arrhythmia specialists is not warranted for the majority of infarct survivors and should be largely reserved for patients with serious, symptomatic arrhythmias.



Author Affiliations

From the Divisions of Cardiology (Drs Stevenson and Ridker) and Preventive Medicine (Dr Ridker), Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.


Footnotes

Reprints: William G. Stevenson, MD, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115.

Clinical Cardiology section editors: William A. Gaasch, MD, University of Massachusetts Medical School, Worcester; Margaret A. Winker, MD, Senior Editor, JAMA.

This article is one of a series sponsored by the American Heart Association.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Outcomes After Ventricular Fibrillation Out-of-Hospital Cardiac Arrest: Expanding the Chain of Survival
Bunch et al.
Mayo Clin Proc. 2005;80:774-782.
ABSTRACT  

Outcomes and In-hospital Treatment of Out-of-Hospital Cardiac Arrest Patients Resuscitated From Ventricular Fibrillation by Early Defibrillation
Bunch et al.
Mayo Clin Proc. 2004;79:613-619.
ABSTRACT  

Effectiveness of implantable defibrillators for preventing arrhythmic events and death: A Meta-Analysis
Lee et al.
J Am Coll Cardiol 2003;41:1573-1582.
ABSTRACT | FULL TEXT  

TASK FORCE ON SUDDEN CARDIAC DEATH, EUROPEAN SOCIETY OF CARDIOLOGY: Summary of Recommendations
Priori et al.
Europace 2002;4:3-18.
ABSTRACT  

Task Force on Sudden Cardiac Death of the European Society of Cardiology
Priori et al.
Eur Heart J 2001;22:1374-1450.
 

Is programmed stimulation in survivors of myocardial infarction helpful?
DiMarco
J Am Coll Cardiol 2001;37:1908-1909.
FULL TEXT  

The Multicenter Automatic Defibrillator Implantation Trial: MADIT Provides the Basis for Developing Therapeutic Strategy for Patients With Severely Depressed Ventricular Ejection Fraction With Nonsustained Ventricular Tachycardia
Saksena and Giorgberidze
J CARDIOVASC PHARMACOL THER 1997;2:229-234.
 

Referral of Patients With Myocardial Infarction and Low Ejection Fraction to Arrhythmia Specialists
Goff
JAMA 1996;276:1634-1634.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1996 American Medical Association. All Rights Reserved.